The stock of Invivyd Inc (IVVD) has gone up by 12.87% for the week, with a 61.52% rise in the past month and a -3.33% drop in the past quarter. The volatility ratio for the week is 6.61%, and the volatility levels for the past 30 days are 9.91% for IVVD. The simple moving average for the past 20 days is 29.33% for IVVD’s stock, with a 22.87% simple moving average for the past 200 days.
Is It Worth Investing in Invivyd Inc (NASDAQ: IVVD) Right Now?
Additionally, the 36-month beta value for IVVD is 0.64. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for IVVD is 76.15M and currently, short sellers hold a 10.39% ratio of that float. The average trading volume of IVVD on June 03, 2025 was 2.34M shares.
IVVD) stock’s latest price update
Invivyd Inc (NASDAQ: IVVD)’s stock price has soared by 9.14 in relation to previous closing price of 0.93. Nevertheless, the company has seen a gain of 12.87% in its stock price over the last five trading days. globenewswire.com reported 2025-05-27 that WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD) today announced that results from its CANOPY Phase 3 clinical trial of pemivibart have been published online as an Advance Article in the peer-reviewed journal Clinical Infectious Diseases (CID), available here. The publication, titled “Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)” highlights attractive safety, substantial clinical antiviral activity, the immunobridge between calculated serum virus neutralizing antibody (sVNA) titers and pemivibart and historical clinical efficacy data, and nominally statistically significant and clinically meaningful efficacy of pemivibart versus placebo in a contemporary U.S. population facing, immune-evasive Omicron SARS-CoV-2 viruses.
Analysts’ Opinion of IVVD
Many brokerage firms have already submitted their reports for IVVD stocks, with Guggenheim repeating the rating for IVVD by listing it as a “Buy.” The predicted price for IVVD in the upcoming period, according to Guggenheim is $9 based on the research report published on April 05, 2024 of the previous year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see IVVD reach a price target of $10, previously predicting the price at $4. The rating they have provided for IVVD stocks is “Overweight” according to the report published on March 26th, 2024.
Morgan Stanley gave a rating of “Equal-Weight” to IVVD, setting the target price at $4 in the report published on December 19th of the previous year.
IVVD Trading at 52.95% from the 50-Day Moving Average
After a stumble in the market that brought IVVD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.96% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at IVVD starting from MCGUIRE TERRANCE, who sale 103,474 shares at the price of $0.45 back on Dec 31 ’24. After this action, MCGUIRE TERRANCE now owns 3,066,757 shares of Invivyd Inc, valued at $46,098 using the latest closing price.
MCGUIRE TERRANCE, the Director of Invivyd Inc, sale 83,744 shares at $0.52 during a trade that took place back on Dec 27 ’24, which means that MCGUIRE TERRANCE is holding 3,256,776 shares at $43,647 based on the most recent closing price.
Stock Fundamentals for IVVD
Current profitability levels for the company are sitting at:
- -4.03 for the present operating margin
- 0.93 for the gross margin
The net margin for Invivyd Inc stands at -3.89. The total capital return value is set at -2.73. Equity return is now at value -122.69, with -89.42 for asset returns.
Based on Invivyd Inc (IVVD), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -158.17.
Currently, EBITDA for the company is -173.76 million with net debt to EBITDA at 0.32. When we switch over and look at the enterprise to sales, we see a ratio of 2.05. The receivables turnover for the company is 4.29for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.53.
Conclusion
In conclusion, Invivyd Inc (IVVD) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
